Homepage Top Section2

Novo Nordisk has announced plans to make more than $2.58bn (DKK17bn) investment to expand its manufacturing facilities in Kalundborg, Denmark. The company plans to construct three new manufacturing

The European Commission (EC) has approved Pfizer’s Cibinqo (abrocitinib) to treat moderate-to-severe atopic dermatitis (AD) adult patients. The 100mg and 200mg doses of the oral small molecule drug

Canadian biopharmaceutical firm Arbutus Biopharma has identified many molecules that can inhibit the SARS-CoV-2 nsp5 main protease (Mpro), achieving its first milestone under Covid-19 discovery research and license

Merck’s anti-PD-1 therapy, Keytruda, has obtained approval from the US Food and Drug Administration (FDA) as an adjuvant therapy for stage IIB or IIC melanoma patients aged 12

Valneva stated that it is now focused on securing regulatory approvals for VLA2001 after the positive results from the Phase III trial. The firm also added that it

The move will enable Gilead to leverage AWS machine learning technologies and analytics to accelerate data-driven decision making across the organisation. The technologies are expected to support clinical

Danish pharma company Novo Nordisk has agreed to acquire Dicerna Pharmaceuticals and its ribonucleic acid interference (RNAi) platform in a deal valued at $3.3bn, to expand the RNAi

With this round, the biotechnology firm has raised more than $300m so far. The funding round was led by Ally Bridge Group, TCG Crossover, and Temasek. Among the

Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics. As part of the collaboration, the companies will discover, develop, and